ClinicalTrials.gg
CompletedNCT00629681Updated Jan 25, 2021

A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia

A Phase 4 interventional study of Pregabalin in Painful Diabetic Neuropathy and Post Herpetic Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 46 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
217
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.

Enrollment
11th of 17
217 · median 241
Started
2004
with 1 other
Phase 4
5 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
9 of 17
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 11th largest by enrollment, is one of 2 that started in 2004, is one of 5 in phase 4, and was the 11th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pregabalin in Diabetic Neuropathies, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of pregabalin for the treatment of diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN)

03

Conditions studied

  • Painful Diabetic Neuropathy and Post Herpetic Neuralgia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of DPN or PHN
  • Score on the Numeric Rating Scale of at least 4/10

Exclusion criteria

Exclusion Criteria:

  • Hospitalized patients
  • Neurologic disorders unrelated to DPN or PHN or any severe pain that may confound the assessment of DPN- or PHN-related pain
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    1

    Drug: Pregabalin

Interventions

  • Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.

06

What researchers measure

Primary outcomes

  1. Correlation between global status (as measured by the Clinical Global Impression of Change [CGIC] and the Patient Global Impression of Change [PGIC]) and changes in pain, anxiety, and sleep parameters

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Mean sleep score from patient's daily sleep interference diary

    Time frame: 14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28

  2. Change from baseline in mean sleep score from patient's daily sleep interference diary

    Time frame: End of treatment

  3. Mean anxiety score from patient's daily anxiety diary

    Time frame: 14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28

  4. Adverse events

    Time frame: 14 and 7 days before baseline, baseline, and Days 4, 7, 14, and 28

  5. Change from baseline in Pain Treatment Satisfaction Scale (PTSS) 9 items score

    Time frame: End of treatment

  6. Median time to pain response profile

    Time frame: Over the first week

  7. CGIC and PGIC

    Time frame: End of treatment

  8. Change from baseline in EuroQOL (as measures by EQ-5D)

    Time frame: End of treatment

  9. Change from baseline in mean anxiety score from patient's daily anxiety diary

    Time frame: End of treatment

  10. Change from baseline in Medical Outcomes Study (MOS)-Sleep Scale score

    Time frame: End of treatment

  11. Course of mean pain score of patient's daily pain diary (NRS)

    Time frame: Throughout the study

07

Study locations

46 sites
  • Pfizer Investigational Site
    Aachen, 52064, Germany
  • Pfizer Investigational Site
    Albstadt, 72458, Germany
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Berlin, 10435, Germany
  • Pfizer Investigational Site
    Berlin, 13053, Germany
  • Pfizer Investigational Site
    Bielefeld, 33604, Germany
  • Pfizer Investigational Site
    Celle, 29221, Germany
  • Pfizer Investigational Site
    Deggingen, 73326, Germany
  • Pfizer Investigational Site
    Duisburg, 47051, Germany
  • Pfizer Investigational Site
    Erbach, 64711, Germany
  • Pfizer Investigational Site
    Erfurt, 99089, Germany
  • Pfizer Investigational Site
    Frankfurt, 60311, Germany
  • Pfizer Investigational Site
    Gera, 07548, Germany
  • Pfizer Investigational Site
    Goeppingen, 73033, Germany
  • Pfizer Investigational Site
    Hamburg, 21073, Germany
  • Pfizer Investigational Site
    Hamburg, 22149, Germany
  • Pfizer Investigational Site
    Hamburg, 22607, Germany
  • Pfizer Investigational Site
    Hemsbach, 69502, Germany
  • Pfizer Investigational Site
    Hildesheim, 31134, Germany
  • Pfizer Investigational Site
    Holle, 31188, Germany
  • Pfizer Investigational Site
    Itzehoe, 25524, Germany
  • Pfizer Investigational Site
    Karlsruhe, 76133, Germany
  • Pfizer Investigational Site
    Karlsruhe, 76199, Germany
  • Pfizer Investigational Site
    Katzhuette, 98746, Germany
  • Pfizer Investigational Site
    Leer, 26789, Germany
  • Pfizer Investigational Site
    Leipzig, 04103, Germany
  • Pfizer Investigational Site
    Limburgerhof, 67117, Germany
  • Pfizer Investigational Site
    Ludwigshafen, 67061, Germany
  • Pfizer Investigational Site
    Ludwigshafen, 67069, Germany
  • Pfizer Investigational Site
    Luebeck, 23552, Germany
  • Pfizer Investigational Site
    Luenen, 44534, Germany
  • Pfizer Investigational Site
    Mainz, 55116, Germany
  • Pfizer Investigational Site
    Marl, 45768, Germany
  • Pfizer Investigational Site
    Muenchen, 81479, Germany
  • Pfizer Investigational Site
    Muenster, 48129, Germany
  • Pfizer Investigational Site
    Osnabrueck, 49078, Germany
  • Pfizer Investigational Site
    Recklinghausen, 45657, Germany
  • Pfizer Investigational Site
    Senftenberg, 01968, Germany
  • Pfizer Investigational Site
    Sinsheim, 74889, Germany
  • Pfizer Investigational Site
    Surwold, 26903, Germany
  • Pfizer Investigational Site
    Unterhaching, 82008, Germany
  • Pfizer Investigational Site
    Veitsbronn, 90587, Germany
  • Pfizer Investigational Site
    Weimar, 99425, Germany
  • Pfizer Investigational Site
    Wiesbaden, 65191, Germany
  • Pfizer Investigational Site
    Witten, 58452, Germany
  • Pfizer Investigational Site
    Zwoenitz, 08297, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2008
First posted
Mar 6, 2008
Start
Nov 2004
CompletionActual
Feb 2006
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00629681
Responsible party
Sponsor
First posted
Mar 6, 2008
Start date
Nov 2004
Completion
Feb 2006
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion